Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American ...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

A large U.S. study reveals that more than a quarter of people with hard-to-treat high blood pressure may have an overlooked hormone problem. Elevated cortisol—often linked to stress—was found in 27% ...

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta ...

As Erik Spoelstra and the Heat were looking for solutions within a healthy rotation, he made a move on Wednesday night ...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate ...

The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Chronic Kidney Disease (CKD) has become a growing challenge. A top doctor shared some of its main causes, ways to prevent it ...

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...